AIM
MCRB icon

Aigen Investment Management’s Seres Therapeutics MCRB Stock Holding History

Aigen Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,762
Closed -$179K – 958
2023
Q3 		$179K Buy
3,762
+3,206
+577% +$245K 0.03% 692
2023
Q2 		$53.2K Buy
+556
New +$60.5K 0.01% 701

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aigen Investment Management's MCRB Position: Q4 2023 in Review

Aigen Investment Management sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 3,762 shares — an estimated $179K sold.

Aigen Investment Management first reported a position in MCRB in Q2 2023 and held it in 2 quarters. The position peaked at $179K in Q3 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Aigen Investment Management reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Aigen Investment Management sold 3,762 Seres Therapeutics shares in Q4 2023, an estimated $179K.
  • Aigen Investment Management first reported a position in Seres Therapeutics in Q2 2023 and held it in 2 quarters.
  • Aigen Investment Management's Seres Therapeutics position peaked at $179K in Q3 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Aigen Investment Management's 13F filing for Q4 2023, filed 9 Feb 2024.